

**Performance in Initiating Clinical Research  
Guy's and St Thomas' NHS Foundation Trust  
01 October 2021 to 30 September 2022**

No	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed by Sponsor	Date Site Confirmed	Non Confirmation Status	Date Site Ready to Start	Date of First Participant Recruited	Reasons for delay correspond to
1	22/NE/0062	223732	A first in human feasibility study of T regulatory cells (TR004) for Inflammatory Bowel disease Using (ex vivo) Treg Expansion	29/03/2017	16/05/2022	16/05/2022	05/07/2022	05/07/2022		06/07/2022		Both
2	20/SC/0300	274476	Effect of High-Dose Vitamin D3 on 28-Day Mortality in Adult Critically Ill Patients with Severe Vitamin D DeficiencyThe UK arm of an International Multi-Centre, Placebo-Controlled, Phase III Double-Blind trial	24/02/2021	21/10/2021	16/11/2020	24/03/2022	28/03/2022		04/04/2022	01/07/2022	Sponsor
3	18/NW/0110	236974	NEO21-RS: A phase II randomised study of the cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with oestrogen suppression therapy versus oestrogen suppression therapy alone as neoadjuvant therapy in ER-positive intermediate recurrence score primary breast cancer	06/08/2019	14/07/2022	12/06/2019						Sponsor
4	19/YH/0015	255446	Beta Blockers or placebo for primary prophylaxis of oesophageal varices (BOPPP Trial). A blinded, multi-centre, clinical effectiveness and cost-effectiveness randomised controlled trial	27/02/2020	13/01/2022	24/04/2019	01/02/2022	08/02/2022		08/02/2022	30/03/2022	Neither
5	19/NW/0462	251756	Chronic Endometritis and Recurrent Miscarriage - The CERM trial	18/03/2021	19/01/2022	20/08/2019						NHS Provider
6	19/SC/0311	262176	ASEPTIC: Primary Antibiotic prophylaxis using co-trimoxazole to prevent Spontaneous bacterial Peritonitis in Cirrhosis	28/02/2020	16/03/2022	07/08/2019	06/05/2022	07/06/2022		07/06/2022	03/08/2022	Both
7	21/WS/0105	1003587	A phase III randomised, triple-blind controlled superiority trial of remimazolam (CNS 7056), compared to midazolam, in adults having lower third molar wisdom tooth extraction under intravenous conscious sedation to assess cognitive and motor recovery at normal discharge times.	07/06/2021	05/10/2021	05/10/2021	24/12/2021	24/12/2021		24/12/2021	09/03/2022	NHS Provider
8	21/YH/0028	283502	IMPRESSEd: IMproving facial PROsthesis construction with contactLESS Scanning and Digital workflow. A feasibility cross-over randomised controlled trial of digital versus conventional manufacture for facial prostheses.	23/07/2021	08/12/2021	09/03/2021	11/03/2022	17/03/2022		12/04/2022	19/05/2022	NHS Provider
9	19/EE/0369	257226	A Phase III, multicentre, multinational randomised control trial investigating 1cm v 2cm wide excision margins for primary cutaneous melanoma.	27/10/2021	13/01/2022	04/06/2020	27/01/2022	27/01/2022		27/01/2022	04/04/2022	Neither
10	19/LO/0692	260290	Practical Management of Cognitive and Behavioural Impairment in Motor Neurone Disease: MiNDToolkit Feasibility Study	09/08/2021	05/04/2022	07/06/2019	09/06/2022		Sponsor declined site confirmation			
11	19/NW/0743	261164	A Polatuzumab Vedotin containing Chemo-Immunotherapeutic regimen in patients with Diffuse Large B-Cell Lymphoma unsuitable for full dose R-CHOP Therapy	12/09/2019	14/03/2022	22/09/2020						Sponsor
12	20/NE/0014	272055	Multi-centre, randomised, open-label, blinded endpoint assessed, trial of corticosteroids plus intravenous immunoglobulin (IVIG) and aspirin, versus IVIG and aspirin for prevention of coronary artery aneurysms in Kawasaki disease(KD-CAAP: Kawasaki Disease Coronary Artery Aneurysm Prevention trial)	07/02/2020	14/07/2022	18/02/2020	29/09/2022	27/09/2022				Sponsor
13	19/LO/1064	260639	The TIGHT-K STUDY. Dysrhythmias on the cardiac intensive care unit - does maintenance of high-normal serum potassium levels matter?	27/01/2020	22/06/2022	06/11/2019	06/07/2022	01/08/2022		01/08/2022	28/09/2022	Sponsor
14	21/WM/0019	287988	Laparoscopic Versus Abdominal hysterectomy (LAVA) trial	11/10/2021	04/02/2022	01/03/2021	09/03/2022	16/03/2022		21/03/2022	03/08/2022	Sponsor
15	19/LO/1866	270431	PlasmaLyte Usage and assessment of kidney Transplant Outcomes in children: the PLUTO trial	25/11/2019	08/10/2021	22/12/2019	22/11/2021	22/11/2021		24/11/2021	07/12/2021	NHS Provider
16	19/LO/1624	269485	Research to Improve the Detection and Treatment of Latent Tuberculosis Infection: Diagnostics (RID-TB:Dx)A randomised controlled trial to evaluate the effectiveness of using the RD-1 based C Tb skin test as a replacement for blood-based interferon-γ release assay for detection of latent TB infection and initiation of TB preventive treatment in the UK	17/11/2021	01/06/2022	14/04/2020						Sponsor
17	22/LO/0056	257601	Intra-treatment Image Guided Adaptive Radiotherapy Dose-escalation Study - a Phase 1 multicentre feasibility study	20/12/2019	19/01/2022	12/04/2022	15/06/2022	15/06/2022		16/06/2022	22/08/2022	NHS Provider
18	21/WS/0085	298247	Randomised controlled trial of a facilitated home-based rehabilitation intervention in patients with heart failure with preserved ejection fraction and their caregivers: The REACH-HFpEF Trial	30/01/2022	18/02/2022	12/10/2021	27/04/2022	27/04/2022		19/05/2022		Both
19	20/NS/0030	277440	POINT - A multi-centre randomised trial of surgery versus non-surgical splint treatment for proximal phalanx shaft finger fractures in adults.	17/09/2021	19/04/2022	12/03/2020	24/08/2022	15/09/2022		23/09/2022		NHS Provider
20	21/SC/0178	298182	Pre-hospital Randomised trial of MEDICATION route in out-of-hospital cardiac arrest (PARAMEDIC3)	06/09/2021	20/05/2022	24/08/2021	20/05/2022	20/05/2022		20/05/2022		Neither
21	20/SC/0095	266541	A Phase I Trial of the Hypoxia Modifier Atovaquone in Combination with Radical Concurrent Chemoradiotherapy in Locally Advanced Non-Small Cell Lung Carcinoma	30/12/2021	01/08/2022	11/05/2020	01/08/2022	08/08/2022		09/08/2022	19/08/2022	
22	21/NS/0038	291133	Bracing Adolescent Idiopathic Scoliosis (BASIS) Study – night-time versus full-time bracing in adolescent idiopathic scoliosis	04/05/2021	24/01/2022	08/04/2021	22/02/2022	23/02/2022		04/04/2022		Sponsor

**Performance in Initiating Clinical Research  
Guy's and St Thomas' NHS Foundation Trust  
01 October 2021 to 30 September 2022**

No	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed by Sponsor	Date Site Confirmed	Non Confirmation Status	Date Site Ready to Start	Date of First Participant Recruited	Reasons for delay correspond to
23	21/EE/0256	277601	Clinical and patient reported outcomes following treatment of grade III furcation involved molars. A single-centre single-masked randomised controlled feasibility trial with a Sequential, Multiple Assignment Randomised Trial (SMART) design.	25/02/2020	12/01/2022	12/01/2022	26/05/2022	26/05/2022		26/05/2022	13/06/2022	NHS Provider
24	21/LO/0178	287775	A Phase II/III trial of Primary radiotherapy for Androgen sensitive Prostate cancer patients with Lymph nodes	08/09/2021	09/09/2022	12/04/2021	28/09/2022	26/09/2022				
25	20/LO/1140	281963	Canadian-Australasian Randomised Trial of Screening Kidney Transplant Candidates For Coronary Artery Disease (CARSK study)	16/11/2021	02/08/2022	08/03/2021						Sponsor
26	21/EM/0088	283518	Suprachoroidal Visco-buckLING for the treatment of rhegmatogenous retinal detachment (VIKING): a randomized, controlled, feasibility trial	07/05/2021	30/11/2021	09/06/2021	03/02/2022	09/02/2022		17/02/2022		Sponsor
27	20/LO/1002	269769	Biologics in refractory vasculitis (BIOVAS): A pragmatic, randomised, double-blind, placebo-controlled, modified-crossover trial of biologic therapy for refractory primary non-ANCA associated vasculitis in adults and children	29/03/2021	11/03/2022	03/11/2020	22/08/2022	08/08/2022		22/09/2022		Both
28	22/LO/0051	304825	Evaluation of the Deontics AI platform for personalised, evidence-based treatment planning in multidisciplinary cancer care: Increasing compliance with national standards of care and streamlining MDTs in prostate cancer.	06/10/2021	10/03/2022	10/03/2022						Both
29	20/SS/0089	266798	Xpert MTB/RIF Ultra assay for the detection of Mycobacterium tuberculosis (MTB) in bronchoalveolar lavage (BAL) for pulmonary TB and endobronchial ultrasound guided transbronchial needle aspiration (EBUS-TBNA) samples for mediastinal TB.	08/09/2021	01/04/2022	08/10/2020	04/04/2022	04/04/2022		04/04/2022	14/06/2022	Sponsor
30	20/WM/0302	276338	Comparing the effectiveness of side-lying sleep positioning to back-lying at reducing oxygen desaturation resulting from Obstructive Sleep Apnoea in infants with cleft palate.	26/01/2021	28/09/2022	22/12/2020						
31	21/YH/0006	283434	An International Randomized Controlled Trial to evaluate the effectiveness of a nurse-delivered (FOCUS+) and a webbased(iFOCUS) psychoeducational intervention for people with Advanced cancer and their family caregivers.	30/06/2021	22/02/2022	05/03/2021	01/12/2020	16/03/2022		17/03/2022		Neither
32	21/NW/0269	292922	A virtual peer-to-peer support programme for informal caregivers of individuals with motor neurone disease at risk of becoming or currently technology-dependent: randomised controlled trial	21/12/2020	18/11/2021	18/11/2021	13/01/2022	13/01/2022		13/01/2022	02/09/2022	Both
33	21/LO/0243	291403	Multicentre prospective single-blind wait-list randomised controlled trial, with nested pilot, of the clinical value and economic evaluation of an online physical and emotional wellbeing resource for the improvement of health-related quality of life in people with chronic kidney disease: The Kidney Beam Trial	06/08/2021	07/10/2021	13/04/2021	26/01/2022	01/02/2022		02/02/2022	03/02/2022	Sponsor
34	21/YH/0066	280583	Exploring the utility and acceptability of Faecal Immunochemical Testing (FIT) as a novel intervention for the improvement of Colorectal Cancer (CRC) surveillance in individuals with Lynch Syndrome.	29/03/2021	26/11/2021	25/03/2021	02/12/2021	02/12/2021		02/12/2021	21/02/2022	Neither
35	20/WS/0178	290482	Anaesthesia Choice for Creation of artEriovenous fistulae	16/06/2021	05/10/2021	24/05/2021	02/11/2021	25/11/2021		25/11/2021	01/04/2022	NHS Provider
36	22/EE/0166	1005499	Subcutaneous CT-P13 monotherapy vs combination with immunomodulation when switching from intravenous infliximab in inflammatory bowel disease – AMulticentre, Randomised Withdrawal Trial	06/05/2022	20/07/2022	07/09/2022	20/07/2022	29/09/2022		30/09/2022		Neither
37	22/LO/0081	280257	A randomised controlled trial to assess the clinical-, technical- and cost-effectiveness of a cloud-based, ARTificiallyIntelligent image fusion system in comparison to standard treatment to guide endovascular Aortic aneurysm repair(ARIA)	24/09/2021	31/12/2021	10/02/2022	23/06/2022	07/07/2022		02/09/2022		NHS Provider
38	21/LO/0903	296622	Endometriosis Fertility Index: A Non-Surgical Approach	01/04/2021	17/01/2022	17/01/2022	28/06/2022	28/06/2022		28/06/2022		NHS Provider
39	21/SW/0098	297574	The COACH trial: A randomised controlled trial of cochlear implantation versus hearing aids in adults with severe hearing loss.	06/10/2021	28/12/2021	07/09/2021	21/01/2022	30/01/2022		07/03/2022		Sponsor
40	21/WM/0259	304500	A multicentre randomised controlled trial (RCT) of a virtual self-help cognitive behavioural therapy (CBT) intervention to reduce the impact of hot flush and night sweats (HFNS) symptoms in men with prostate cancer undergoing androgen deprivation therapy (ADT): Managing symptoms during prostate cancer treatment (MANCAN2)	29/10/2021	27/04/2022	16/12/2021	13/05/2022	24/05/2022		27/05/2022		Neither
41	21/EE/0274	299561	BIOMARKER- GUIDED INTERVENTION TO PREVENT ACUTE KIDNEY INJURY AFTER MAJOR NON-CARDIAC SURGERY - THE PROSPECTIVE MULTICENTER RANDOMIZED CONTROLLED INTERVENTIONAL TRIAL	02/04/2021	16/12/2021	16/12/2021	13/01/2022	13/01/2022		13/01/2022	07/04/2022	Neither
42	21/LO/0412	288722	Statins in Organ Donor Management An evaluation of the benefits of a single dose of Simvastatin given to potential organ donors declared dead by neurological criteria on outcomes in organ recipients	14/10/2021	26/01/2022	28/06/2021	03/03/2022	08/03/2022		22/03/2022		NHS Provider
43	21/WS/0032	293749	Experience of Rucaparib as maintenance treatment following platinum based chemotherapy in relapsed ovarian cancer - a UK real world study	27/10/2021	15/12/2021	23/06/2021	13/01/2022	18/01/2022		18/01/2022	07/02/2022	
44	21/LO/0645	299406	AdolesCents Home based InterVention Study (ACHIEVE)	13/05/2021	19/10/2021	19/10/2021	11/11/2021	11/11/2021		11/11/2021	17/11/2021	

**Performance in Initiating Clinical Research  
Guy's and St Thomas' NHS Foundation Trust  
01 October 2021 to 30 September 2022**

No	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed by Sponsor	Date Site Confirmed	Non Confirmation Status	Date Site Ready to Start	Date of First Participant Recruited	Reasons for delay correspond to
45	22/NW/0053	298717	A Feasibility Study and Process Evaluation of an Integrated Support Programme for Adults Following a Diagnosis of Type 1 Diabetes- the Livingwith and Adapting to Diabetes Programme (LADDER)	21/05/2021	06/04/2022	06/04/2022	03/08/2022	03/08/2022		03/08/2022		NHS Provider
46	21/LO/0454	296522	Investigating the impact of faecal microbiota transplant on the clinical phenotype of patients with non-alcoholic fatty liver disease and fibrosis	24/05/2021	11/11/2021	18/08/2021	08/12/2021	10/01/2022		13/01/2022	24/02/2022	NHS Provider
47	22/LO/0163	292223	PROMETHEUS: Prospective Trial of Machine Learning To Help Fetal Ultrasound Scanning	01/06/2021	19/04/2022	19/04/2022	15/08/2022	15/08/2022		15/08/2022		NHS Provider
48	21/LO/0823	297153	An Integrated Primary Care-based Programme of Pre-pregnancy Care to Improve Pregnancy Outcomes in Women with Type 2 diabetes: A Multi-method Study of Implementation, System Adaptation and Performance.	04/06/2021	23/12/2021	23/12/2021	09/06/2022	09/06/2022		09/06/2022		NHS Provider
49	21/NW/0199	293515	PROTEUS: A Prospective randomised controlled Trial Evaluating the Use of AI in Stress Echocardiography	16/07/2021	25/01/2022	22/07/2021						NHS Provider
50	21/WA/0184	288397	Interleukin-1 receptor antagonist treatment for refractory complex regional pain syndrome	02/12/2021	02/03/2022	15/09/2021	07/06/2022	16/06/2022				NHS Provider
51	21/LO/0853	300145	Haemodynamic effects of Reducing Left Ventricular Afterload with Impella or Intra-aortic Balloon Counterpulsation during Venous Arterial Extracorporeal Membrane Oxygenation in Cardiogenic Shock	09/09/2021	30/11/2021	13/01/2022	02/03/2022	02/03/2022		02/03/2022		NHS Provider
52	21/EE/0187	296881	Pragmatic randomised trial of High or Standard Phosphate Targets in End-stage kidney disease (PHOSPHATE)	14/12/2021	05/09/2022	01/09/2021						
53	21/EM/0205	289580	Randomised controlled trial comparing online behavioural sleep intervention with standard care in children with rolandic epilepsy	15/03/2022	22/08/2022	10/12/2021	25/08/2022	25/08/2022		26/08/2022		Neither
54	22/LO/0034	295131	To assess the postoperative changes in fibrinolysis and the utility of tranexamic acid in patients with inherited bleeding disorders.	11/10/2021	04/01/2022	27/05/2022						Neither
55	21/WA/0368	306220	Long COVID Personalised Self-management Support Evaluation (LISTEN)	08/02/2022	13/04/2022	13/12/2021	25/05/2022	06/06/2022		06/06/2022	25/08/2022	Both
56	22/YH/0051	311106	Randomised trial of intra-articular injection of lidocaine versus placebo in inflammatory arthritis (RT- IIIIA)	10/01/2022	24/03/2022	24/03/2022	29/03/2022	29/03/2022		29/03/2022	13/04/2022	
57	22/SC/0146	311123	A randomised, controlled study to compare visual performance at distance, intermediate and near, refractive outcome, contrast sensitivity, stereoacuity, patient satisfaction, patient related health economics and rotational lens stability following bilateral, micro-monovision insertion of two toric, aspheric, hydrophobic acrylic intraocular lenses: The TECNIS Eyhance Toric II IOL and the Alcon Acrysof IQ Toric IOL	24/01/2022	09/06/2022	09/06/2022	21/09/2022	21/09/2022		21/09/2022		Sponsor
58	22/YH/0175	307417	Comparison of unilateral CI vs. Bimodal stimulation in prosodic perception	18/02/2022	29/07/2022	29/07/2022	30/08/2022	30/08/2022		30/08/2022		Neither
59	22/LO/0574	314107	Managing pain in people with Crohn's Disease: Feasibility Testing of an Acceptance and Commitment Group Therapy intervention.	30/05/2022	05/09/2022							
60	22/NW/0057	310380	Body image, psychological distress, shame and disordered eating in patients in a Tier 3 weight management service receiving an online delivered, group based Compassion Focused Therapy (CFT) informed psychological intervention	27/05/2022	30/06/2022	25/05/2022	31/01/2022	28/07/2022		28/07/2022		Neither
61	20/NW/0331	274096	A Phase 1/2 Study of REGN4018 Administered Alone or in Combination with Cemiplimab in Patients with Platinum-Resistant Ovarian Cancer	05/11/2020	28/09/2022	11/01/2021						
62	21/LO/0040	215432	A 24-week with possible extension, prospective, multicenter, randomized, double blind, placebo-controlled, 2-parallel group with a randomization 1:1, phase 3 study to compare efficacy and safety of oral masitinib to placebo in treatment of patients with smouldering or indolent severe systemic mastocytosis with handicap, unresponsive to optimal symptomatic treatment.	19/07/2021	05/01/2022	19/02/2021	03/02/2022	12/02/2022		14/02/2022		Sponsor
63	20/SC/0026	271167	An Open-Label, Long-Term Safety, Tolerability, and Efficacy Study of TEV-50717 (Deutetrabenazine) for the Treatment of Dyskinesia in Cerebral Palsy in Children and Adolescents (Open RECLAIM-DCP)	05/07/2020	09/12/2021	01/05/2020	09/12/2021	10/12/2021		10/12/2021	25/01/2022	NHS Provider
64	20/SC/0218	280504	Open-label, non-randomized Phase 1, multicenter study to assess radium-223 biodistribution in participants with bone metastatic castration resistant prostate cancer (CRPC) receiving radium-223 dichloride treatment.	18/01/2021	17/11/2021	25/08/2020	15/12/2021	17/12/2021		22/12/2021		Neither
65	20/WA/0098	275346	Randomized, Open-label, 2-Arm, Multicenter, Phase 3 Study of Venetoclax and Azacitidine Versus Best Supportive Care as Maintenance Therapy for Patients with Acute Myeloid Leukemia in First Remission After Conventional Chemotherapy (VIALE-M)	24/08/2020	15/10/2021	29/04/2020	29/10/2021	02/11/2021		03/11/2021	26/05/2022	Sponsor

**Performance in Initiating Clinical Research  
Guy's and St Thomas' NHS Foundation Trust  
01 October 2021 to 30 September 2022**

No	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed by Sponsor	Date Site Confirmed	Non Confirmation Status	Date Site Ready to Start	Date of First Participant Recruited	Reasons for delay correspond to
66	21/FT/0107	1003678	A multi-center, double blinded and open label extension study to evaluate the efficacy and safety of ligelizumab as retreatment, self-administration therapy and monotherapy in Chronic Spontaneous Urticaria patients who completed studies CQGE031C2302, CQGE031C2303, CQGE031C2202 and CQGE031C1301	27/09/2021	08/12/2021	14/09/2021	13/12/2021	14/12/2021		16/12/2021	06/01/2022	
67	19/LO/1215	261663	A PHASE 3B, OPEN-LABEL, SINGLE-ARM, ROLLOVER STUDY TO EVALUATE LONG-TERM SAFETY IN SUBJECTS WHO HAVE PARTICIPATED IN OTHER LUSPATERCEPT (ACE-536) CLINICAL TRIALS	05/05/2022	10/06/2022	11/02/2020	05/07/2022	07/07/2022		08/07/2022		Sponsor
68	21/LO/0176	288923	A Phase 3 Study of Pembrolizumab (MK-3475) in Combination with Concurrent Chemoradiation Therapy Followed by Pembrolizumab with or without Olaparib, Compared to Concurrent Chemoradiation Therapy Followed by Placebo in Participants with Newly Diagnosed Untreated Limited-Stage Small Cell Lung Cancer (LS-SCLC)	11/02/2021	09/11/2021	19/04/2021	08/12/2021	08/12/2021		16/12/2021		Sponsor
69	20/ES/0067	1003032	A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study To Evaluate The Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately To Severely Active Systemic Lupus Erythematosus	04/02/2022	27/04/2022	08/09/2020	16/05/2022	18/05/2022		20/05/2022		Neither
70	22/SS/0074	306338	TRIDENT/EF-32: A Phase III Randomized, open-label study of Optune® (TFields, 200KHZ) concomitant with radiation therapy and temozolomide for the treatment of newly diagnosed glioblastoma	25/08/2022	05/08/2022							NHS Provider
71	21/EE/0039	290104	A phase 3, multicenter, randomized, open-label, active-controlled study of trastuzumab deruxtecan (T-DXd) versus trastuzumab emtansine (T-DM1) in subjects with high-risk HER2- positive primary breast cancer who have residual invasive disease in breast or axillary lymph nodes following neoadjuvant therapy (DESTINY-Breast05)	13/05/2021	15/11/2021	27/07/2021	23/11/2021	23/11/2021		23/11/2021		Neither
72	20/PR/0102	280883	A40 EFL Registry: A Multicenter Prospective Study to Determine the Role of EFL in Patients with Chronic Obstructive Pulmonary Disease (COPD) Receiving Home Mechanical Ventilation	02/11/2020	22/03/2022	03/09/2020	08/04/2022	13/04/2022		14/04/2022		Sponsor
73	20/EM/0209	286545	A Phase 3 Randomized, Placebo-controlled, Double-Blind Study of Niraparib in combination with Abiraterone Acetate and Prednisone (AA-P) and ADT versus Abiraterone Acetate and Prednisone and ADT in Subjects with Metastatic Castration Sensitive Prostate Cancer (mCSPC) with DNA-repair defects	04/01/2021	10/12/2021	13/10/2020	17/12/2021	23/12/2021		23/12/2021	05/04/2022	Neither
74	21/LO/0122	290974	A single-arm, Phase II study to evaluate PD-L1 Expression in Non-Small Cell Lung Cancer using the 99mTc Labelled Anti-PD-L1 single domain antibody (NM-01)	25/06/2021	14/01/2022	08/04/2021	25/01/2022	04/02/2022		08/02/2022	03/05/2022	Sponsor
75	21/LO/0177	290367	A Phase 3, Randomized, Double-blind, Active-Control Study of CPI-0610 and Ruxolitinib vs. Placebo and Ruxolitinib in JAKi Treatment Naive MF Patients	10/09/2021	16/02/2022	19/04/2021	31/03/2022	04/04/2022		05/04/2022		NHS Provider
76	21/ES/0017	1003434	A Randomized Open-Label, Phase 3 Study to Evaluate Imetelstat (GRN163L) Versus Best Available Therapy (BAT) in Patients with Intermediate-2 or High-risk Myelofibrosis (MF) Refractory to Janus Kinase (JAK)-Inhibitor	15/01/2021	01/03/2022	09/03/2021	16/05/2022	18/07/2022		22/07/2022		NHS Provider
77	21/EM/0070	292658	A PROSPECTIVE, RANDOMIZED, MULTICENTER STUDY TO COMPARE THE SAFETY AND EFFECTIVENESS OF THE OMNI® SURGICAL SYSTEM AND THE ISTENT INJECT IN PSEUDOPHAKIC EYES WITH OPEN ANGLE GLAUCOMA. THE TRIDENT EUROPEAN TRIAL	12/04/2021	05/11/2021	28/04/2021	25/03/2022	13/04/2022		14/04/2022		Both
78	21/FT/0017	290947	A Phase II Study of cemiplimab, an anti-PD-1 monoclonal antibody, and ISA101b vaccine in patients with recurrent/metastatic HPV16 positive Oropharyngeal Cancer who have experienced disease progression with prior anti-PD-1 therapy Oropharyngeal Cancer (OPC) and disease progression with prior anti-PD-1 therapy	05/05/2022	14/04/2022	02/02/2021	11/05/2022	16/05/2022		17/05/2022		Neither
79	21/LO/0559	296584	A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Study Evaluating the Efficacy and Safety of Subcutaneous Anifrolumab in Adult Patients with Systemic Lupus Erythematosus	10/03/2022	06/05/2022	18/02/2022	28/07/2022	09/08/2022		09/08/2022		Both
80	21/SC/0246	1003592	A Phase 2 Open Label, Multi-Center Study Evaluating the Safety and Efficacy of Autologous Tumor Infiltrating Lymphocytes (TILs) in Subjects with Advanced Melanoma	09/02/2022	25/02/2022	25/11/2021	12/05/2022	18/05/2022		20/05/2022		Both
81	21/FT/0009	288367	A Randomised, Open-Label Phase 2/3 Study Comparing Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in Participants with Advanced Non-small Cell Lung Cancer Who Have Progressed on Prior Anti PD (L1) Therapy and Chemotherapy (COSTAR LUNG)	18/03/2021	08/12/2021	21/04/2021	25/01/2022	27/01/2022		28/01/2022		Sponsor
82	20/LO/1099	1003048	A Phase 3, Randomized, Multi-center, Open-label Study of Trastuzumab Deruxtecan (T-DXd) Versus Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy in the Metastatic Setting (DESTINY-Breast06)	21/04/2022	29/04/2022	26/11/2020	16/05/2022	18/05/2022		18/05/2022	13/06/2022	
83	21/FT/0091	299590	A Phase 1b/2 Multicentre, Open-label, Modular, Dose-finding and Dose-expansion Study to Explore the Safety, Tolerability, and Anti-tumour Activity of Trastuzumab Deruxtecan (T-DXd) in Combination with other Anti-cancer Agents in Patients with HER2-positive Metastatic Breast Cancer (DESTINY Breast07)	07/05/2021	30/03/2022	02/12/2021	20/04/2022	01/05/2022		03/05/2022		Sponsor

**Performance in Initiating Clinical Research  
Guy's and St Thomas' NHS Foundation Trust  
01 October 2021 to 30 September 2022**

No	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed by Sponsor	Date Site Confirmed	Non Confirmation Status	Date Site Ready to Start	Date of First Participant Recruited	Reasons for delay correspond to
84	20/LO/0229	277929	A Phase 1/2 Multiple Ascending-Dose Study in Subjects With Homocystinuria Due to Cystathionine β-Synthase (CBS) Deficiency to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of ACN00177	21/09/2021	13/10/2021	15/05/2020	14/10/2021	14/10/2021		18/10/2021		Neither
85	21/NE/0022	292581	A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Atrasentan in Patients with IgA Nephropathy at Risk of Progressive Loss of Renal Function	06/04/2021	08/02/2022	19/04/2021	25/04/2022	26/04/2022		27/04/2022		NHS Provider
86	21/FT/0006	292412	A Phase 2 Basket Study of Tucatinib in Combination with Trastuzumab in Subjects with Previously Treated, Locally Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations	24/02/2022	15/03/2022	06/04/2021	06/05/2022	20/05/2022		25/05/2022		NHS Provider
87	20/LO/1158	273531	A Phase 1b, First-in-Human, Dose Escalation and Expansion Study of XMT-1536 In Patients with Solid Tumors Likely to Express NAPI2b	17/06/2021	04/05/2022	17/12/2020	11/05/2022	12/05/2022		16/05/2022	30/06/2022	NHS Provider
88	21/YH/0078	1003505	A Randomized Open-Label Phase III Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Subjects with Metastatic or Locally Advanced Unresectable Urothelial Cancer	13/04/2021	31/03/2022	14/05/2021	27/04/2022	06/05/2022		11/05/2022		NHS Provider
89	21/WA/0165	289626	An Adaptive, Randomized, Placebo-controlled, Double-blind, Multi-center Study of Oral FT-4202, a Pyruvate Kinase Activator in Patients with Sickle Cell Disease	09/09/2021	22/10/2021	02/07/2021	17/11/2021	03/12/2021		09/12/2021		NHS Provider
90	21/FT/0125	302263	A phase 3b, multi-center, open-label, treatment optimization study of oral asciminib in patients with Chronic Myelogenous Leukemia in chronic phase (CML-CP) previously treated with 2 or more tyrosine kinase inhibitors	19/11/2021	21/03/2022	24/09/2021	29/03/2022	30/03/2022		31/03/2022		NHS Provider
91	21/LO/0501	282560	A Double-Blind, Randomized, Placebo-Controlled, Safety and Efficacy Study of ANAVEX2-73 in Patients with Rett Syndrome	29/09/2021	17/03/2022	01/09/2021	13/04/2022	21/04/2022		22/04/2022	18/05/2022	
92	21/FT/0039	292422	A Multicenter, Open-Label Phase 1/2 Trial Evaluating the Safety, Tolerability, and Efficacy of MORAb-202, a Folate Receptor Alpha (FRα)-Targeting Antibody-Drug Conjugate (ADC) in Subjects With Selected Tumor Types	08/09/2021	09/07/2022	23/06/2021	18/07/2022	21/07/2022		02/08/2022		NHS Provider
93	20/YH/0320	290498	A multinational, open-label, randomised, controlled trial to investigate efficacy and safety of NNC0365-3769 (Mim8) in adults and adolescents with haemophilia A with or without inhibitors.	11/11/2020	25/10/2021	11/08/2021	15/11/2021	17/11/2021		18/11/2021	11/03/2022	Sponsor
94	20/SC/0232	279454	A Phase 1/2 Safety, Tolerability, and Efficacy Study of BMN 270, an Adeno-Associated Virus Vector-Mediated Gene Transfer of Human Factor VIII in Hemophilia A Patients with Active or Prior Inhibitors	03/08/2021	25/03/2022	25/09/2020	27/03/2022	31/03/2022		05/04/2022		Sponsor
95	22/EM/0020	303180	A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Mitapivat in Subjects With Sickle Cell Disease	14/02/2022	10/06/2022	17/03/2022	24/06/2022	02/09/2022		28/09/2022		NHS Provider
96	21/SC/0247	1003793	A Randomized, Multicenter, Phase 3 Study of Zanidatamab in Combination with Chemotherapy with or without Tislelizumab in Subjects with HER2-positive Unresectable Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma (GEA)	28/07/2021	21/07/2022	17/09/2021	27/07/2022	11/08/2022		12/08/2022		Neither
97	21/EM/0102	294776	A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ravulizumab in Adult Participants With Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN)	20/08/2021	02/12/2021	09/06/2021	17/12/2021	20/12/2021		21/12/2021	30/03/2022	NHS Provider
98	21/LO/0467	300194	A dose confirmation study of FLT180a (adeno-associated viral vector containing the Padua variant of a codonoptimized human Factor IX gene) in adult subjects with hemophilia B	22/12/2021	20/01/2022	19/08/2021	24/01/2022	26/01/2022		26/01/2022	17/05/2022	NHS Provider
99	21/WS/0044	1003689	A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Pembrolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy for the Treatment of Chemotherapy-Candidate Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (HR+/HER2-) Metastatic Breast Cancer (KEYNOTE-B49)	26/04/2021	30/05/2022	15/06/2021	15/06/2022	15/06/2022		30/06/2022		Sponsor
100	21/FT/0089	298957	A Phase III, multi-center, randomized (1:1), open-label, active-controlled study to assess the efficacy and safety of alpelisib (BYL719) in combination with olaparib as compared to single agent cytotoxic chemotherapy, in participants with no germline BRCA mutation detected, platinum-resistant or refractory, high-grade serous ovarian cancer	17/01/2022	12/07/2022	15/09/2021	29/07/2022	02/08/2022		03/08/2022		NHS Provider
101	21/FT/0046	292809	An Exploratory, Multicenter, Randomized, Double Blind study of Clinical Outcomes, Tolerability, and Safety of 2 Doses of Oral Pantoprazole in Pediatric participants aged 1 to 11 years and 12 to 17 years Who Require Maintenance Therapy for Healed Erosive Esophagitis	23/03/2021	14/10/2021	16/06/2021	31/01/2022	01/02/2022		03/02/2022		Both
102	21/EM/0023	289484	A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of AKCEA-APOCIII-LRX Administered Subcutaneously to Patients with Familial Chylomicronemia Syndrome (FCS)	25/03/2021	14/10/2021	24/03/2021	21/10/2021	28/10/2021		01/11/2021	16/03/2022	NHS Provider
103	21/SC/0001	290972	A Phase 1/2a, Dose Escalation Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered CDK 003 in Healthy Adult Participants and Intralesionally Administered CDK 003 in Patient participants with Cutaneous T-cell Lymphoma (CTCL)	31/08/2021	04/03/2022	12/02/2021	08/04/2022	21/04/2022		25/04/2022		NHS Provider

**Performance in Initiating Clinical Research  
Guy's and St Thomas' NHS Foundation Trust  
01 October 2021 to 30 September 2022**

No	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed by Sponsor	Date Site Confirmed	Non Confirmation Status	Date Site Ready to Start	Date of First Participant Recruited	Reasons for delay correspond to
104	21/YH/0268	1004313	A Phase IIb, Randomised, Double Blind, Placebo Controlled, Parallel Group, Multicentre Dose Ranging Subcutaneous Study of an Anti OX40L Monoclonal Antibody (KY1005) in Moderate to Severe Atopic Dermatitis	01/02/2022	08/04/2022	25/01/2022	21/04/2022	21/04/2022		12/05/2022	25/07/2022	NHS Provider
105	21/FT/0104	303394	A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of BIIB059 in Adult Participants With Active Systemic Lupus Erythematosus Receiving Background Nonbiologic Lupus Standard of Care	08/12/2021	25/05/2022	04/10/2021	25/05/2022	07/06/2022		09/06/2022		Both
106	21/LO/0719	297112	Safety, efficacy and exposure of subcutaneously administered NNC0365-3769(Mim8) prophylaxis in paediatric patients with haemophilia A with or without FVIII inhibitors	06/09/2021	29/05/2022	29/11/2021	11/08/2021	12/08/2022		12/08/2022		Both
107	21/FT/0074	297419	A phase 3 extension trial of DELTA 1 and DELTA 2 to evaluate the long-term safety of a twice-daily treatment with delgocitinib cream 20 mg/g as needed for up to 36 weeks in adult subjects with chronic hand eczema (DELTA 3)	09/09/2021	15/11/2021	28/07/2021	17/11/2021	18/11/2021		09/12/2021	14/12/2021	
108	21/LO/0764	299215	Perivenous Dexamethasone Therapy: Examining Reduction of Inflammation after Thrombus Removal to Yield Benefit in Subacute and Chronic Iliofemoral DVT	09/03/2022	07/03/2022	10/12/2021	24/03/2022	01/04/2022		05/04/2022		Neither
109	21/EE/0169	1003809	A Two-part Phase IIa Randomised, Double-blind, Placebo-controlled, Dose ranging, Multi centre Study to Assess Efficacy and Safety of Three Inhaled Dose Levels of AZD1402 Administered as a Dry Powder Twice Daily for Four Weeks in Adults with Asthma on Medium Dose Inhaled Corticosteroids	03/12/2021	16/03/2022	10/08/2021	14/04/2022	20/04/2022		22/04/2022		Sponsor
110	21/WA/0236	1003660	Open-Label, Phase 2 Study to Assess the Safety of Mogamulizumab Given Every 4 Weeks Following Induction in Participants with Relapsed/Refractory Cutaneous T-Cell Lymphoma (CTCL)	26/07/2021	29/09/2022							
111	21/FT/0043	290151	A Randomized Phase 3 Double-Blinded Study Comparing Efficacy of Niraparib to Placebo in Participants with either HER2-Negative BRCA-Mutated or Triple-negative Breast Cancer with Molecular Disease Based on Presence of Circulating Tumor DNA after Definitive Therapy	07/05/2021	25/10/2021	17/05/2021	22/11/2021	14/12/2021		15/12/2021		NHS Provider
112	21/NW/0039	294490	A Modular, Phase II, Open-Label, Multicentre Study to Assess the Preliminary Efficacy and Safety of RXC004, in Patients with Advanced Solid Tumours that have Progressed following Therapy with Current Standard of Care	03/08/2021	07/04/2022	18/03/2021	23/05/2022	24/05/2022		24/05/2022		NHS Provider
113	21/WA/0107	295734	An Open-Label Study to Investigate the Safety and Pharmacokinetics of Multiple Ascending Doses of Antisense Oligonucleotide STK-001 in Children and Adolescents with Dravet Syndrome	16/09/2021	03/02/2022	03/06/2021	11/02/2022	21/02/2022		24/02/2022		NHS Provider
114	21/FT/0058	293068	Phase 1 Study Exploring the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Select Advanced Solid Tumors	04/10/2021	25/05/2022	17/05/2021	05/07/2022	14/07/2022		14/07/2022		NHS Provider
115	21/LO/0763	301126	Perivenous Dexamethasone Therapy: Examining Reduction of Inflammation after Thrombus Removal to Yield Benefit in Acute Femoropopliteal DVT	09/03/2022	07/03/2022	05/01/2022	24/03/2022	01/04/2022		05/04/2022		Neither
116	21/EM/0232	1004080	A Phase 2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of KER-050 as Monotherapy or in Combination with Ruxolitinib in Participants with Myelofibrosis	29/03/2022	16/05/2022	05/11/2021						NHS Provider
117	21/NW/0302	303839	A Phase 3, Open-Label, Randomized Study of Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy Compared with Platinum-Based Chemotherapy in Patients with EGFR-Mutated Advanced or Metastatic Non-Small Cell Lung Cancer After Osimertinib Failure	30/11/2021	21/07/2022	27/01/2022	05/08/2022	11/08/2022		12/08/2022		NHS Provider
118	21/LO/0276	297789	A First in Human Study of the Menin-KMT2A (MLL1) Inhibitor JNJ-75276617 in Participants with Acute Leukemia	02/08/2021	16/11/2021	28/05/2021	01/12/2021	07/12/2021		08/12/2021	23/06/2022	Neither
119	21/YH/0279	296994	Prospective, multicentre single-arm Post-Market Clinical Follow-up (PMCF) study to evaluate safety and performance of the BeYond Venous Self- Expanding Stent BYV – PMCF	14/06/2022	26/07/2022	06/12/2021	15/08/2022	17/08/2022		19/08/2022		Sponsor
120	21/LO/0486	1003856	Safety and efficacy of inhaled pegylated adrenomedullin (PEG-ADM) in patients suffering from Acute Respiratory Distress Syndrome (ARDS): a double-blind, randomized, placebo-controlled, multicenter Phase 2a/b clinical trial	25/08/2021	25/01/2022	25/08/2021	27/01/2022	10/02/2022		17/02/2022	07/06/2022	NHS Provider
121	22/FT/0034	1005125	A 52 week, multi-center, randomized, double-blind placebo-controlled study to assess the clinical efficacy and safety of ligelizumab (QGE031) in decreasing the sensitivity to peanuts in patients with peanut allergy	27/07/2022	29/07/2022	25/04/2022	30/08/2022	28/09/2022				NHS Provider
122	21/SW/0112	1003834	A Phase III, Multicentre, International Study with a Parallel, Randomised, Double-blind, Placebo-controlled, 2 Arm Design to Assess the Efficacy and Safety of Selumetinib in Adult Participants with NF1 who have Symptomatic, Inoperable Plexiform Neurofibromas (KOMET).	18/01/2022	13/10/2021	23/09/2021	01/04/2022	04/04/2022		05/04/2022		Both
123	21/WS/0109	300932	A PHASE 2/3 STUDY OF ALX148 IN PATIENTS WITH ADVANCED HER2-OVEREXPRESSING GASTRIC/GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA (ASPEN-06)	19/11/2021	30/05/2022	01/11/2021	13/06/2022	13/06/2022		17/06/2022		NHS Provider
124	22/LO/0101	296997	SUCCESS (SelUtion, safety, effiCaCy, hEalth economicS and promS) PTA Study	23/02/2022	09/06/2022	19/04/2022	14/07/2022	17/08/2022		18/08/2022	22/08/2022	NHS Provider

**Performance in Initiating Clinical Research  
Guy's and St Thomas' NHS Foundation Trust  
01 October 2021 to 30 September 2022**

No	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed by Sponsor	Date Site Confirmed	Non Confirmation Status	Date Site Ready to Start	Date of First Participant Recruited	Reasons for delay correspond to
125	22/WA/0041	305714	A Phase 3, Multicenter, Open-label, Long-term, Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects with Erythropoietic Protoporphyrin (EPP) or X-Linked Protoporphyrin (XLP)	31/03/2022	19/05/2022	30/03/2022	25/05/2022	09/06/2022		21/06/2022		Sponsor
126	21/LO/0776	1004145	Phase 2a Open-Label Study in Infants with REspiratory Syncytial VIRus Lower RespirAtory Tract Infection, Followed by a Double-blind, Placebo controlled Part, to Evaluate the Safety, Tolerability, Pharmacokinetics and Antiviral Effect of RV521 (REVIRAL 1)	20/04/2022	28/04/2022	19/11/2021	04/05/2022	06/05/2022		11/05/2022		Sponsor
127	22/NW/0070	1003872	A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study of BLU-263 in Indolent Systemic Mastocytosis	21/02/2022	31/08/2022	21/02/2022	06/09/2022	29/09/2022				
128	21/WA/-249	300758	A randomized trial of ultrasound-facilitated, catheter-directed, thrombolysis versus anticoagulation for acute intermediate-high risk pulmonary embolism: The higher-risk pulmonary embolism thrombolysis study	07/03/2022	25/03/2022	30/09/2021	05/04/2022	06/04/2022		07/04/2022		NHS Provider
129	21/SC/0267	1003806	A Randomized, Head-to-head, Single-blind Study to Compare the Response to Treatment with Subcutaneous Abatacept vs Adalimumab, on Background Methotrexate, in Adults with Early, Seropositive Rheumatoid Arthritis Who Have "Shared Epitope" HLA Class II Risk Alleles and Have an Inadequate Response to Methotrexate	08/10/2021	15/02/2022	27/10/2021	21/02/2022	26/02/2022		02/03/2022		Neither
130	21/WM/0270	1004246	A PHASE II, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO EVALUATE THE SAFETY, EFFICACY, AND PHARMACODYNAMICS OF 52 WEEKS OF TREATMENT WITH BASMISANIL IN CHILDREN WITH DUP15Q SYNDROME	28/02/2022	29/03/2022	05/01/2022	31/03/2022	01/04/2022		04/04/2022		NHS Provider
131	22/LO/0208	1004546	A DOUBLE-BLIND, RANDOMIZED, PLACEBO CONTROLLED, TWO PERIOD CROSS-OVER STUDY WITH AN OPEN LABEL EXTENSION TO EVALUATE THE EFFICACY AND SAFETY OF ORVEPITANT IN CHRONIC COUGH IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS	29/03/2022	21/07/2022	06/05/2022	26/07/2022	02/08/2022		02/08/2022		Sponsor
132	21/LO/0422	1003607	A Multicenter, Randomized, Double-Blind, Parallel-Group Study to Assess the Efficacy and Safety of Oral Etrasimod as Induction and Maintenance Therapy for Moderately to Severely Active Crohn's Disease	09/11/2021	13/05/2022	02/08/2021	16/05/2022	17/05/2022		17/05/2022		NHS Provider
133	21/SC/0242	1003589	A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Safety and Efficacy of Inclacumab in Participants with Sickle Cell Disease Experiencing Vasoocclusive Crises	18/11/2021	22/10/2021	23/09/2021	11/04/2022	26/04/2022		16/05/2022		NHS Provider
134	21/EE/0217	299172	A PHASE 2 OPEN-LABEL, MULTICENTER CLINICAL STUDY OF THE SAFETY, EFFICACY, PHARMACOKINETIC, AND PHARMACODYNAMIC PROFILES OF CGT9486 AS A SINGLE AGENT IN PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS	22/09/2021	23/11/2021	10/11/2021	07/12/2021	08/12/2021		08/12/2021	15/12/2021	
135	21/WA/0221	1003867	A PHASE 1/2, OPEN-LABEL, MULTICENTER STUDY TO EVALUATE A DOSING REGIMEN WITH TWO STEP-UP PRIMING DOSES AND LONGER DOSING INTERVALS OF ELRANATAMAB (PF-06863135) MONOTHERAPY IN PARTICIPANTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA	08/12/2021	01/04/2022	13/08/2021	18/05/2022	26/05/2022		14/06/2022		Both
136	22/EM/0091	1004374	A Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Safety and Efficacy of ABBV- 154 in Subjects with Moderately to Severely Active Crohn's Disease (CD)	06/04/2022	26/08/2022	04/07/2022	02/09/2022	02/09/2022		06/09/2022		
137	21/SC/0241	1003787	A Randomized, Double-blind, Placebo-controlled, Multicenter Study of a Single Dose of Inclacumab to Reduce Re-admission in Participants with Sickle Cell Disease and Recurrent Vaso-occlusive Crises	04/10/2021	22/03/2022	21/09/2021	25/04/2022	26/04/2022		02/08/2022		NHS Provider
138	22/LO/0125	1004415	JNJ-77242113 - A Phase 2b Multicenter, Randomized, Placebo-Controlled, Dose-Ranging Trial to Evaluate the Efficacy and Safety of an Oral Biologic Therapy for Treatment of Moderate to Severe Plaque Psoriasis	27/01/2022	19/05/2022	30/03/2022	23/05/2022	25/05/2022		25/05/2022	05/07/2022	Neither
139	21/EE/0242	1004172	An open-label dose-escalation study evaluating the safety, pharmacokinetics and antiviral activity of IMC-M113V in HLA-A*02:01 positive subjects with chronic HIV infection who are virologically suppressed	08/11/2021	22/03/2022	26/11/2021	30/03/2022	30/03/2022		31/03/2022		Sponsor
140	21/SC/0214	1003789	A Translational Phase 1/2 Dose-Escalation and Expansion Study to Determine Safety, Tolerability, and Recommended Phase 2 Dose of RSO-021 in Patients with Malignant Pleural Effusion due to Advanced/Metastatic Solid Tumors including Mesothelioma	07/07/2022	12/09/2022	27/09/2021	22/09/2022	26/09/2022				
141	21/NE/0208	304113	A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors	14/01/2022	21/03/2022	01/12/2021	29/03/2022	29/03/2022		31/03/2022		NHS Provider
142	21/NW/0181	1003808	A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF OBINUTUZUMAB IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS	02/02/2022	17/06/2022	15/09/2021	30/06/2022	12/07/2022		14/07/2022		Sponsor
143	22/SC/0033	1004431	A 24-week, randomised, assessor-blinded, active-controlled, parallel-group, phase 3, 2-arm trial to compare the efficacy and safety of delgocitinib cream 20 mg/g twice-daily with alitretinoin capsules once-daily in adult participants with severe chronic hand eczema	21/01/2022	13/06/2022	08/03/2022	15/06/2022	21/06/2022		23/06/2022		NHS Provider
144	22/YH/0098	1005083	A single (assessor) blinded, randomised, parallel-group, monotherapy trial to evaluate the pharmacokinetic and safety of tralokinumab in children (age 2 to <12 years) with moderate-to-severe atopic dermatitis	10/06/2022	13/07/2022	08/06/2022	23/08/2022	28/09/2022				NHS Provider

**Performance in Initiating Clinical Research  
Guy's and St Thomas' NHS Foundation Trust  
01 October 2021 to 30 September 2022**

No	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed by Sponsor	Date Site Confirmed	Non Confirmation Status	Date Site Ready to Start	Date of First Participant Recruited	Reasons for delay correspond to
145	21/EM/0244	303091	A Multi-Center, Open Label, Extension Study Evaluating the Safety and Efficacy of Bomedemstat for the Treatment of Patients with Myeloproliferative Neoplasms (MPNs) Enrolled in a Prior Bomedemstat Clinical Study	12/10/2021	23/12/2021	29/12/2021	10/01/2022	12/01/2022		13/01/2022		NHS Provider
146	21/SC/0399	1004257	A PHASE III, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY OF LURBINECTEDIN PLUS ATEZOLIZUMAB COMPARED WITH ATEZOLIZUMAB AS MAINTENANCE THERAPY IN PARTICIPANTS WITH EXTENSIVE-STAGE SMALL-CELL LUNG CANCER (ES-SCLC) FOLLOWING FIRST-LINE INDUCTION THERAPY WITH CARBOPLATIN, ETOPOSIDE AND ATEZOLIZUMAB	22/11/2021	04/05/2022	23/02/2022	12/05/2022	18/05/2022		30/05/2022		NHS Provider
147	21/NW/0343	1004224	A Phase III, Double-blind, Randomised, Placebo-Controlled, International Study to assess the Efficacy and Safety of Adjuvant Osimertinib versus Placebo in Participants with EGFR mutation-positive Stage IA2-IA3 Non-small Cell Lung Cancer, following Complete Tumour Resection	14/01/2022	11/07/2022	20/01/2022	26/07/2022	25/08/2022		30/08/2022		NHS Provider
148	22/LO/0214	1004972	A Multicentre, Single-arm, Phase 3b Efficacy and Safety Study of Tezepelumab 210 mg Administered Subcutaneously to Reduce Oral Corticosteroid Use and Asthma Exacerbations in Adult Participants with Severe Asthma on High-dose Inhaled Corticosteroid plus Long-acting $\beta$ 2 Agonist and Long-term Oral Corticosteroid Therapy (WAYFINDER)	07/03/2022	26/08/2022	19/04/2022	02/09/2022	06/09/2022		07/09/2022		
149	22/SC/0085	1005149	A multiple ascending dose (MAD) safety, tolerability and efficacy study of VRDN-001, a humanized monoclonal antibody directed against the IGF-1 receptor, in normal healthy volunteers (NHVs) and subjects with thyroid eye disease (TED)	25/04/2022	12/07/2022	06/05/2022	18/08/2022	14/09/2022		20/09/2022		NHS Provider
150	18/LO/0666	242700	Extended Access of Momelotinib for Subjects with Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)	02/03/2022	09/06/2022	15/05/2018	08/07/2022	18/07/2022		25/07/2022		NHS Provider
151	22/HRA/0060	1004941	A Phase 2/3, Randomized, Stratified, Observer-blind Study to Evaluate the Immunogenicity and Safety of mRNA-1273.529 (B.1.1.529, Omicron variant) Booster Vaccine	21/01/2022	13/04/2022	03/02/2022	13/04/2022	14/04/2022		14/04/2022	21/04/2022	
152	22/LO/0282	313514	A PROSPECTIVE, MULTICENTER MASKED CLINICAL TRIAL TO EVALUATE THE SAFETY AND EFFECTIVENESS OF THE MINIJECT CS627 IMPLANT IN SUBJECTS WITH OPEN ANGLE GLAUCOMA	04/07/2022	29/07/2022	01/08/2022	18/08/2022	26/08/2022		30/08/2022		Sponsor
153	22/EM/0047	307457	A Phase 2, Long-Term Extension (LTE) Study with Elsbrutinib and Upadacitinib Given Alone or in Combination (ABBV599) in Subjects with Moderately to Severely Active Systemic Lupus Erythematosus Who Have Completed the M19-130 Phase 2 Randomized Controlled Trial (RCT)	25/02/2022	22/03/2022	09/03/2022	29/03/2022	31/03/2022		31/03/2022	02/05/2022	Neither
154	22/SC/0099	1005346	Prospective cohort study to monitor the emergence of SARS-CoV-2 spike viral variants in immunocompromised non-hospitalised patients exposed to sotrovimab in Great Britain: LUNAR study	21/03/2022	06/06/2022	12/05/2022	08/06/2022	16/06/2022		20/06/2022	11/07/2022	
155	22/NI/0036	304974	Clinical Impact of the iBox as an early Intervention tool: A prospective randomised controlled trial to assess the use of a software predicting allograft survival in the follow-up of kidney transplanted patients.	29/04/2022	10/06/2022	24/03/2022	24/06/2022	12/07/2022		12/07/2022	05/08/2022	
156	22/YH/0115	1005233	A study comparing the effect and safety of once weekly dosing of somapacitan with daily Norditropin® as well as evaluating long-term safety of somapacitan in a basket study design in children with short stature either born small for gestational age or with Turner syndrome, Noonan syndrome, or idiopathic short stature	04/06/2022	06/09/2022	12/07/2022	15/09/2022	16/09/2022		21/09/2022		
157	22/WM/0066	1004762	A Phase 3, Multicenter, Randomized, Partially Blinded, Palivizumab-Controlled Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of MK-1654 in Infants and Children at Increased Risk for Severe RSV Disease	10/05/2022	09/08/2022	28/04/2022	10/09/2022					Both
158	22/NE/0074	1005249	A PHASE 2, RANDOMIZED, OPEN-LABEL STUDY OF ENCORAFENIB AND CETUXIMAB PLUS PEMBROLIZUMAB VERSUS PEMBROLIZUMAB ALONE IN PARTICIPANTS WITH PREVIOUSLY UNTREATED BRAF V600E-MUTANT, MSI-H/DMMR METASTATIC COLORECTAL CANCER	21/04/2022	22/09/2022	24/06/2022	23/09/2022	26/09/2022		26/09/2022		
159	22/8C/0132	1005180	A Phase IIIb randomized open-label study of nirsevimab (versus no intervention) in preventing hospitalizations due to respiratory syncytial virus in infants (HARMONIE)	20/06/2022	04/08/2022	14/06/2022	22/08/2022	23/08/2022		01/09/2022		Sponsor
160	22/LO/0310	1004164	A MULTICENTER, OPEN-LABEL PHASE IV STUDY TO EVALUATE OVERALL HEALTH, PHYSICAL ACTIVITY, AND JOINT OUTCOMES, IN PARTICIPANTS AGED $\geq$ 13 AND < 70 YEARS WITH SEVERE OR MODERATE HEMOPHILIA A WITHOUT FVIII INHIBITORS ON EMICIZUMAB PROPHYLAXIS	11/04/2022	22/08/2022	20/06/2022	25/08/2022	25/08/2022		02/09/2022		Sponsor
161	22/SC/0071	1005082	A Phase 3, Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) Versus Investigator's Choice of Chemotherapy in Patients who are not Candidates for PD-1/PD-L1 Inhibitor Therapy in First-line Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer	18/05/2022	26/09/2022	19/04/2022						
162	18/LO/0359	242661	A Phase 3, Randomized, Double-Blind, Placebo Controlled Study of Voxelotor (GBT440) in Pediatric Participants with Sickle Cell Disease and an Open-label Study in Infants with Sickle Cell Disease (HOPE Kids 2)	14/11/2021	07/03/2022	04/01/2019		07/06/2022		10/06/2022		Both



**Performance in Initiating Clinical Research  
Guy's and St Thomas' NHS Foundation Trust  
01 October 2021 to 30 September 2022**

No	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed by Sponsor	Date Site Confirmed	Non Confirmation Status	Date Site Ready to Start	Date of First Participant Recruited	Reasons for delay correspond to
163	22/PR/0153	311132	Detecting cancers Earlier Through Elective plasma-based CancerSEEKTesting – Ascertain Serial Cancer patients to Enable New DiagnosticII (DETECT-ASCEND 2)	24/05/2022	16/09/2022	18/07/2022	26/09/2022	26/09/2022		27/09/2022		
164	20/NW/0435	271173	Zephyrus II: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Pamrevlumab in Subjects with Idiopathic Pulmonary Fibrosis (IPF)	21/04/2021	07/10/2021	13/01/2021	04/11/2021	08/11/2021		11/02/2022	21/04/2022	
165	21/LO/0333	1003552	A Phase2b, Dose Ranging, Randomised, Double-blind, Placebo-Controlled, Multicenter Study of Rodatristat Ethyl in Patients with Pulmonary Arterial Hypertension.	28/04/2021	25/10/2021	06/07/2021	11/02/2022	15/02/2022		22/02/2022	17/05/2022	
166	21/WM/0282	304570	Real World Study of the Tendyne™ Mitral Valve System to Treat Mitral Regurgitation (RESOLVE-MR)(Tendyne™ PMCF Study)	23/12/2021	05/01/2022	25/02/2022	05/01/2022	25/02/2022		17/03/2022	26/04/2022	
167	20/EM/0015	247350	Beyond Allergic Th2 Severe Asthma	13/05/2021	05/01/2022	25/03/2020	21/04/2022	22/04/2022		22/04/2022		Sponsor
168	20/SC/0240	274093	Identifying a safe and tolerated dose of Imatinib forpatients with Pulmonary Arterial Hypertension (PAH)	04/02/2020	26/01/2022	28/07/2020	07/02/2022	22/02/2022		08/03/2022	22/03/2022	
169	21/WM/0283	298372	Development and validation of the use of Video games and virtual reality to enable Autonomous Remote monitoring of OTotoxicity in high-risk population groups (VAROT).	21/01/2022	04/02/2022	04/02/2022	04/02/2022	04/02/2022		16/03/2022	05/04/2022	
170	21/NI/0196	308539	“Aveir™ DR i2i Study”Aveir Dual-Chamber Leadless i2i IDE Study	24/11/2021	18/02/2022	07/02/2022	22/02/2022	23/02/2022		17/03/2022	28/03/2022	
171	21/PR/1738	300440	Efficacy of GLP-1 agonist Semaglutide in acute pulmonary embolisms: a biomarker-driven proof of concept open label phase II study	02/02/2022	16/03/2022	02/02/2022	28/03/2022	28/03/2022		28/03/2022	21/04/2022	
172	21/NW/0294	1003950	A Phase 3, Randomized, Double-blind, Controlled Study Evaluating the Efficacy andSafety of VX-121 Combination Therapy in Subjects With Cystic Fibrosis Who AreHeterozygous for F508del and a Minimal Function Mutation (F/MF)	13/10/2021	16/03/2022	15/12/2021	22/03/2022	22/03/2022		27/06/2022	15/08/2022	
173	21/SC/0406	303156	Assessment and validation of a device for measuring hydrogen peroxide in exhaled breath condensate in patients with COPD	07/01/2022	27/03/2022	11/01/2022	01/04/2022	25/04/2022		25/04/2022	10/05/2022	
174	22/FT/0003	1004766	A Phase 3 Open-label Study Evaluating the Long-term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor Triple Combination Therapy in Cystic Fibrosis Subjects 2 Years and Older	01/04/2022	01/04/2022	22/02/2022	03/05/2022	04/05/2022		04/05/2022	17/05/2022	
175	21/YH/0027	289572	A Randomized controlled trial to Assess the Safety and Efficiency of a self-Contained sampling device /disposable bronchoscope system versus usual sAmPLing procedure. RASECAL	21/04/2022	21/04/2022	15/06/2021	04/05/2022	04/05/2022		04/05/2022	25/05/2022	
176	18/EM/0217	244390	Autonomic Regulation Therapy to Enhance Myocardial Function and Reduce Progression of Heart Failure with Heart Failure with Reduced Ejection Fraction	25/11/2021	22/04/2022	12/09/2018	22/04/2022	27/04/2022		05/05/2022		NHS Provider
177	22/NS/0055	307300	Remote monitoring to predict and prevent asthma attacks in preschool children	27/05/2022	27/05/2022	13/06/2022	27/05/2022	21/06/2022		27/06/2022	14/07/2022	
178	21/YH/0050	292050	Small Annuli Randomized To Evolut or Sapien Trial	22/03/2022	04/08/2022	13/04/2021	04/08/2022		Sponsor declined site confirmation			
179	22/EM/0102	310751	A Multicenter, Cross-sectional Study to Characterize the Distribution of Lipoprotein(a)Levels Among Patients With Documented History of Atherosclerotic Cardiovascular Disease (ASCVD)	19/07/2022	08/08/2022	10/05/2022	07/09/2022	07/09/2022				
180	22/EE/0033	1004406	A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects with Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium avium Complex (MAC)	06/07/2020	14/03/2022	07/04/2022	06/07/2022	07/07/2022		08/07/2022		Neither
181	21/NW/0307	1003951	A Phase 3, Randomized, Double-blind, Controlled Study Evaluating the Efficacy and Safety of VX-121 Combination Therapy in Subjects With Cystic Fibrosis Who Are Homozygous for F508del or Heterozygous for F508del and a Gating (F/G) or Residual Function (F/RF) Mutation	29/11/2021	30/03/2022	06/01/2022	31/03/2022	01/04/2022		26/07/2022	25/08/2022	Neither
182	21/LO/0070	291518	A PHASE III RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF PRM-151 IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS	18/03/2021	30/05/2022		25/07/2022	25/07/2022		13/09/2022		Neither
183	20/WM/0312	279463	A subject and investigator blinded, randomized, placebo-controlled, repeat-dose, multicenter study to investigate efficacy, safety, and tolerability of CMK389 in patients with chronic pulmonary sarcoidosis	18/11/2020	09/06/2022		12/07/2022	12/07/2022		25/07/2022		Neither